Clinical outcomes from routine practice confirm ocrelizumab effectiveness in relapsing MS, with low rates of disability worsening over 4 years.

The Brain Care Score is a tool encompassing 12 modifiable risk factors that may help measure brain health and identify stroke risk.

The FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1).